A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

IsraelRecruitingPHASE1, PHASE2

Conditions

Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • University of Colorado Anschutz Medical Campus ( Site 1110), Aurora, Colorado, United States

    Study coordinator · 303-724-6268
  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111), Miami, Florida, United States

    Study coordinator · 305-243-1754
  • University of Chicago ( Site 1108), Chicago, Illinois, United States

    Study coordinator · 773-702-6149
  • Dana Farber Cancer Institute ( Site 1105), Boston, Massachusetts, United States

    Study coordinator · 617-632-6049
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103), Hackensack, New Jersey, United States

    Study coordinator · 551-996-5863
  • Roswell Park Cancer Institute ( Site 1107), Buffalo, New York, United States

    Study coordinator · 716-845-3167
  • Providence Portland Medical Center ( Site 1101), Portland, Oregon, United States

    Study coordinator · 503-215-5696
  • Sarah Cannon Research Institute ( Site 7001), Nashville, Tennessee, United States

    Study coordinator · 844-482-4812
  • Medical College of Wisconsin ( Site 1112), Milwaukee, Wisconsin, United States

    Study coordinator · 414-805-8900
  • Hospital Universitario Austral ( Site 2204), Pilar, Buenos Aires, Argentina

    Study coordinator · 02304482000
  • Sanatorio Parque ( Site 2203), Rosario, Santa Fe Province, Argentina

    Study coordinator · +5493416955611
  • Princess Alexandra Hospital ( Site 5300), Woolloongabba, Queensland, Australia

    Study coordinator · +61731766577
  • Monash Health ( Site 5301), Clayton, Victoria, Australia

    Study coordinator · +61417607416
  • FALP ( Site 2100), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56224205098
  • Pontificia Universidad Catolica de Chile ( Site 2102), Santiago, Region M. de Santiago, Chile

    Study coordinator · +5690233407
  • Bradfordhill ( Site 2101), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56229490970
  • Beijing Cancer Hospital ( Site 5401), Beijing, Beijing Municipality, China

    Study coordinator · (010) 88121122
  • Fujian Cancer Hospital ( Site 5413), Fuzhou, Fujian, China

    Study coordinator · 0591-62002053
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology ( Site 5403), Nanjing, Jiangsu, China

    Study coordinator · 025-83106666
  • Shanghai Chest Hospital ( Site 5400), Shanghai, Shanghai Municipality, China

    Study coordinator · 021-22200000
  • Shanghai Pulmonary Hospital ( Site 5405), Shanghai, Shanghai Municipality, China

    Study coordinator · 15801709047
  • West China Hospital of Sichuan University ( Site 5416), Chengdu, Sichuan, China

    Study coordinator · 02885423237
  • The First Affiliated Hospital, Zhejiang University ( Site 5404), Hangzhou, Zhejiang, China

    Study coordinator · 13675843246
  • Rambam Health Care Campus ( Site 3202), Haifa, Israel

  • Shaare Zedek Medical Center ( Site 3200), Jerusalem, Israel

    Study coordinator · 026555768
  • Rabin Medical Center ( Site 3203), Petah Tikva, Israel

    Study coordinator · +97239378101
  • Sheba Medical Center ( Site 3201), Ramat Gan, Israel

    Study coordinator · 97235304498
  • Aichi Cancer Center ( Site 5000), Nagoya, Aichi-ken, Japan

    Study coordinator · +81-52-762-6111
  • National Cancer Center Hospital East ( Site 5001), Kashiwa, Chiba, Japan

    Study coordinator · +81-4-7133-1111
  • Kansai Medical University Hospital ( Site 5004), Hirakata, Osaka, Japan

    Study coordinator · +81-72-804-2808
  • Cancer Institute Hospital of JFCR ( Site 5002), Koto, Tokyo, Japan

    Study coordinator · +81-3-3520-0111
  • Seoul National University Hospital ( Site 5100), Seoul, South Korea

    Study coordinator · +82220723559
  • Severance Hospital, Yonsei University Health System ( Site 5102), Seoul, South Korea

    Study coordinator · +82215991004
  • Samsung Medical Center ( Site 5101), Seoul, South Korea

    Study coordinator · +82234101795
  • HOSPITAL CLÍNIC DE BARCELONA ( Site 3310), Eixample, Barcelona, Spain

    Study coordinator · +34932275402
  • Institut Català d'Oncologia - L'Hospitalet ( Site 3317), L'Hospitalet de Llobregat, Barcelona, Spain

    Study coordinator · +34932607744
  • Hospital Clinico San Carlos... ( Site 3316), Madrid, Madrid, Comunidad de, Spain

    Study coordinator · 34913303000x484804
  • Hospital Universitari Vall d'Hebron ( Site 3311), Barcelona, Spain

    Study coordinator · +34934894158
  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 3315), Madrid, Spain

    Study coordinator · +34915504800ext2805
  • Hospital Universitario HM Sanchinarro ( Site 3313), Madrid, Spain

    Study coordinator · +34917567984
  • Hospital Universitario Virgen de la Victoria ( Site 3312), Málaga, Spain

    Study coordinator · +34671594566
  • National Cheng Kung University Hospital ( Site 5202), Tainan, Taiwan

    Study coordinator · +88662353535
  • Taipei Medical University Hospital ( Site 5201), Taipei, Taiwan

    Study coordinator · +886227372181
  • Hacettepe Universite Hastaneleri ( Site 3410), Ankara, Turkey (Türkiye)

    Study coordinator · +903123055000
  • Ankara Bilkent Sehir Hastanesi ( Site 3412), Ankara, Turkey (Türkiye)

    Study coordinator · +90312 552 6084
  • National Institute for Health Research UCLH Clinical Research Facility ( Site 3902), London, London, City of, United Kingdom

    Study coordinator · +442034472930
  • The Clatterbridge Cancer Centre ( Site 3903), Liverpool, United Kingdom

    Study coordinator · 00441515565000
  • The Christie NHS Foundation Trust ( Site 3901), Manchester, United Kingdom

    Study coordinator · +441614463000
Study leads
  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC